Venus Remedies Ltd
VENUSREM NSE
Venus Remedies Ltd
HealthcareNSE: VENUSREM BSE: 526953 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹2,159 Cr
Volatility
Moderate
P/E Ratio
18.49
EBITDA
₹147 Cr
Return on Equity
8.08%
Debt to Equity
0.02
Book Value
₹496.56
52W High
₹2,044.3
52W Low
₹424
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Venus Remedies Ltd insights
29 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company is almost debt free.
- Company has delivered good profit growth of 21.8% CAGR over last 5 years
Weaknesses
3- Stock is trading at 3.34 times its book value
- The company has delivered a poor sales growth of 7.18% over past five years.
- Company has a low return on equity of 10.5% over last 3 years.
Growth Rate
Revenue Growth
15.07% ↗
Net Income Growth
123.55% ↗
Cash Flow Change
131.80% ↗
ROE
38.36% ↗
ROCE
51.90% ↗
EBITDA Margin (Avg.)
49.09% ↗
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 95 | 168 | 143 | 195 | 109 | 170 | 177 | 195 | 137 | 193 | 180 | 259 | 179 |
| Expenses | 85 | 150 | 131 | 176 | 97 | 163 | 158 | 166 | 122 | 162 | 143 | 196 | 145 |
| Operating Profit | 10 | 18 | 12 | 19 | 11 | 8 | 18 | 29 | 15 | 31 | 38 | 63 | 34 |
| OPM % | 11% | 11% | 8% | 10% | 10% | 4.5% | 10% | 15% | 11% | 16% | 21% | 24% | 19% |
| Other Income | 2 | 3 | 2 | 4 | 2 | 8 | 12 | 7 | 3 | 2 | 3 | 5 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 8 | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 6 | 6 | 7 | 7 | 7 |
| PBT | 5 | 14 | 8 | 17 | 7 | 9 | 25 | 31 | 13 | 26 | 33 | 62 | 30 |
| Tax % | 77% | 31% | 12% | 40% | 82% | 61% | 21% | 32% | 24% | 24% | 24% | 23% | 24% |
| Net Profit | 1 | 10 | 7 | 11 | 1 | 4 | 20 | 21 | 10 | 20 | 26 | 48 | 23 |
| EPS in Rs | 0.88 | 7.44 | 5.12 | 7.86 | 0.91 | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 | 19.14 | 35.54 | 17.18 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 455 | 407 | 400 | 372 | 322 | 335 | 544 | 597 | 552 | 596 | 640 | 770 | 811 |
| Expenses | 366 | 326 | 349 | 333 | 289 | 295 | 490 | 535 | 492 | 537 | 577 | 622 | 645 |
| Operating Profit | 89 | 81 | 51 | 39 | 33 | 41 | 54 | 62 | 60 | 60 | 64 | 147 | 166 |
| OPM % | 20% | 20% | 13% | 11% | 10% | 12% | 10% | 10% | 11% | 10% | 10% | 19% | 20% |
| Other Income | 1 | 2 | 2 | 2 | -3 | -4 | 43 | 8 | 10 | 12 | 31 | 13 | 12 |
| Interest | 41 | 38 | 34 | 35 | 25 | 13 | 13 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 46 | 42 | 40 | 34 | 34 | 32 | 35 | 34 | 32 | 26 | 23 | 26 | 26 |
| PBT | 3 | 4 | -22 | -28 | -30 | -8 | 49 | 36 | 38 | 45 | 72 | 134 | 152 |
| Tax % | -95% | 52% | -21% | 11% | -4% | 24% | -27% | -12% | 30% | 36% | 37% | 23% | — |
| Net Profit | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 41 | 27 | 28 | 45 | 103 | 116 |
| EPS in Rs | 4.51 | 1.49 | -13.84 | -24.87 | -23.15 | -8.1 | 50.05 | 30.46 | 19.88 | 21.31 | 33.9 | 76.9 | 86.92 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 13% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 445 | 426 | 376 | 350 | 320 | 311 | 388 | 427 | 447 | 474 | 548 | 650 |
| Borrowings | 321 | 335 | 312 | 307 | 298 | 220 | 51 | 43 | 42 | 41 | 2 | 12 |
| Other Liabilities | 64 | 70 | 65 | 82 | 102 | 100 | 104 | 97 | 98 | 98 | 153 | 178 |
| Total Liabilities | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 854 |
| Fixed Assets | 444 | 452 | 406 | 389 | 364 | 289 | 262 | 241 | 216 | 219 | 229 | 232 |
| CWIP | 78 | 80 | 66 | 65 | 65 | 25 | 25 | 25 | 26 | 21 | 26 | 51 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 19 | 84 | 238 |
| Other Assets | 319 | 310 | 293 | 297 | 304 | 330 | 269 | 314 | 339 | 368 | 376 | 333 |
| Total Assets | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 854 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 68 | 47 | 59 | 31 | 45 | 78 | 132 | 41 | 37 | 37 | 86 | 156 |
| Investing | -67 | 3 | -18 | 8 | -11 | -5 | 57 | -17 | -58 | -8 | -77 | -182 |
| Financing | -1 | -46 | -44 | -39 | -35 | -73 | -162 | -9 | -1 | -1 | -1 | -3 |
| Net Cash Flow | -1 | 3 | -4 | 0 | -1 | 0 | 27 | 14 | -22 | 28 | 9 | -29 |
| Free Cash Flow | 59 | 46 | 41 | 19 | 35 | 70 | 132 | 41 | 29 | 24 | 69 | 118 |
| CFO/OP | 76 | 58 | 116 | 79 | 139 | 190 | 245 | 66 | 61 | 89 | 160 | 129 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51 | 55 | 43 | 46 | 43 | 33 | 21 | 24 | 51 | 49 | 64 | 49 |
| Inventory Days | 194 | 219 | 226 | 246 | 286 | 296 | 129 | 118 | 132 | 125 | 97 | 122 |
| Days Payable | 40 | 38 | 48 | 52 | 72 | 77 | 76 | 47 | 56 | 55 | 89 | 107 |
| Cash Conversion Cycle | 204 | 236 | 221 | 240 | 257 | 252 | 74 | 95 | 127 | 120 | 72 | 64 |
| Working Capital Days | 54 | 69 | 54 | 25 | -1 | 73 | 71 | 82 | 109 | 118 | 86 | 97 |
| ROCE % | 6% | 5% | 2% | 1% | 1% | 2% | 8% | 8% | 8% | 9% | 11% | 22% |
Documents
1
Disclosure Of Social Media Post On Transfer Of Physical Shares.
4 May - Company shared social media links for special window to re-lodge transfer requests of physical shares. 4 May - Company shared social media links for special window to re-lodge transfer requests of physical shares.
2
Compliances-Reg.24(A)-Annual Secretarial Compliance
6 May - Submitted annual secretarial compliance report for FY ended 31 March 2026; no non-compliances reported. 6 May - Submitted annual secretarial compliance report for FY ended 31 March 2026; no non-compliances reported.
3
Disclosure Of Social Media Post On Transfer Of Physical Shares.
4 May - Company shared social media links for special window to re-lodge transfer requests of physical shares. 4 May - Company shared social media links for special window to re-lodge transfer requests of physical shares.
4
Announcement under Regulation 30 (LODR)-Newspaper Publication
5 May - Newspaper publication of Notice to shareholders about transfer of physical shares as per SEBI circular. 5 May - Newspaper publication of Notice to shareholders about transfer of physical shares as per SEBI circular.
5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Regulation 74(5) compliance certificate submitted for quarter ended 31 March 2026. 8 Apr - Regulation 74(5) compliance certificate submitted for quarter ended 31 March 2026.
2
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association 21 Aug 2026
General_Announcements
Frequently Asked Questions about Venus Remedies Ltd
What does Venus Remedies Ltd do?
Incorporated in 1989, Venus Remedies
Ltd is a research-based pharmaceutical company focused on complex injectable formulations across critical care, oncology, anti-infectives and specialty therapies. It operates across 100+ countries, with a product basket of 195+, 1,100+ marketing authorisation...
Where is Venus Remedies Ltd (VENUSREM) listed?
Venus Remedies Ltd is listed on the Indian stock exchanges. It is listed on NSE: VENUSREM and BSE: 526953. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Venus Remedies Ltd belong to?
Venus Remedies Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Venus Remedies Ltd?
Venus Remedies Ltd has a market capitalisation of approximately ₹2158.63 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Venus Remedies Ltd?
The Price-to-Earnings (PE) ratio of Venus Remedies Ltd is 18.49. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Venus Remedies Ltd?
Over the past 52 weeks, Venus Remedies Ltd has traded between a low of ₹424 and a high of ₹2,044.3. This range helps investors understand the stock's price volatility and recent trading levels.
Does Venus Remedies Ltd pay dividends?
Yes, Venus Remedies Ltd has a dividend yield of 0.60%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Venus Remedies Ltd?
Venus Remedies Ltd has a Return on Equity (ROE) of 8.08%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Venus Remedies Ltd on Tapetide?
On Tapetide, you can view Venus Remedies Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1989, Venus Remedies Ltd is a research-based pharmaceutical company focused on complex injectable formulations across critical care, oncology, anti-infectives and specialty therapies. It operates across 100+ countries, with a product basket of 195+, 1,100+ marketing authorisations and 700+ dossiers filed.{# {# https://www.bseindia.com/xml-data/corpfiling/AttachHis/29971821-bfab-4659-a9d8-7cf5dc170d02.pdf#page=36 #} #}
Website venusremedies.com
CEO Mr. Pawan Chaudhary
Employees 1,298
Listed 2006-12-20
Face Value ₹ 10
Issued Size 1,33,66,988